Join
Live feed
·
PRReleasevia Quantisnow
Fortress Biotech Inc. logo

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

ByQuantisnow·Wall Street's wire, on your screen.
FBIO· Fortress Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBIO (Fortress Biotech Inc.) and more on Quantisnow.